Evidence map›Paper›PMID 41932358›Full record

ArticleChemMedChem2026

Targeting Kinetoplastid Parasites with ProTide Prodrugs: A Proof-of-Concept Study.

Silvester Lowe, Vishal Satikuvar, Tanjia M Syeda, Monica Cal, Pascal Mäser, Marcel Kaiser, Hachemi Kadri

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in ChemMedChem, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Silvester LoweDepartment of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, London, UK.
Vishal SatikuvarDepartment of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, London, UK.
Tanjia M SyedaDepartment of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, London, UK.
Monica CalDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute (Swiss TPH), University of Basel, Basel, Switzerland.
Pascal MäserDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute (Swiss TPH), University of Basel, Basel, Switzerland.
Marcel KaiserDepartment of Medical Parasitology and Infection Biology, Swiss Tropical and Public Health Institute (Swiss TPH), University of Basel, Basel, Switzerland.
Hachemi KadriDepartment of Pharmacy, School of Life Sciences, Pharmacy and Chemistry, Kingston University, London, UK.ORCID https://orcid.org/0000-0003-3964-9045

Funding

Global Challenges Research Fund MR/P027989/1ARoyal Society of Chemistry R21-6118257436
6 · The paper itself

Abstract

Neglected tropical diseases (NTDs) remain a major global health challenge, particularly in low- and middle-income countries. Kinetoplastid parasites causing Chagas disease, leishmaniasis, and African trypanosomiasis rely on host purine salvage pathways, making nucleoside analogues attractive therapeutic candidates. However, their clinical utility is limited by poor cellular uptake and rapid metabolism. Herein, we report the application of the ProTide prodrug technology, a clinically validated approach that enhances the intracellular delivery of nucleoside monophosphates for the treatment of kinetoplastids infections. As a proof of concept, a focused library of zidovudine (AZT) and cordycepin ProTide prodrugs was designed, synthesized, and evaluated for antiparasitic activity against T. b. rhodesiense, T. cruzi, and L. donovani, as well as for cytotoxicity in L6 rat myoblasts. Out of these, compound 16 exhibited substantial serum stability and potent activity (IC

Indexed as

Antiprotozoal AgentsKinetoplastidaProdrugsProTidesAnimalsDose-Response Relationship, DrugLeishmania donovaniMolecular StructureParasitic Sensitivity TestsProof of Concept StudyRatsStructure-Activity RelationshipTrypanosoma brucei rhodesienseTrypanosoma cruziAntiprotozoal AgentsProdrugsProTidescordycepinkinetoplastidsneglected tropical diseasesnucleoside analoguesproTide

Identifiers

PMID41932358
PMCPMC13048835

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.